Infective endocarditis
Imaging findings on cardiac CT and brain MRI, empiric antimicrobial choices and dosing, and when central nervous system coverage matters in infective endocarditis (IE).
Imaging findings
Typical findings on multi-detector computed tomography (MDCT) mainly involve high-resolution anatomical detail of cardiac structures and perivalvular extension, while MRI — especially cerebral MRI — is crucial for detecting embolic complications of IE.
MDCT (cardiac CT)
MDCT offers higher spatial resolution than echocardiography and is unaffected by acoustic shadowing, making it highly valuable, especially for prosthetic valves.
- Perivalvular lesions: MDCT excels at evaluating perivalvular extension — abscesses, fistulas, pseudoaneurysms, and extension of infection into the cardiac skeleton. Compared with transesophageal echocardiography (TEE), MDCT is superior for identifying abscesses and pseudoaneurysms and gives more accurate anatomical information.
- Aortic root and tricuspid valve: evaluation of the aortic root and coronary arteries; effective imaging of the tricuspid annulus and leaflets.
- Calcification: evaluation of bulky annular and leaflet calcium.
- Vegetations: high sensitivity (96%) and specificity (99%), although small vegetations (<4 mm) are more often missed by CT than by TEE.
- Surgical planning: non-invasive assessment for coronary artery disease.
- Extracardiac structures: can detect primary or IE-related pulmonary disease such as abscesses or necrotic deposits.
Brain MRI
MRI’s main role in IE is detecting cerebral embolic events; cerebral MRI is the most sensitive technique for cerebral emboli. Neurologic complications are common in IE, affecting up to 55% of patients, often without symptoms.
A systematic review and meta-analysis of 21 studies (2,133 patients) with suspected or confirmed IE reported these pooled frequencies on brain MRI:[4]
| Finding | Pooled frequency | Definition |
|---|---|---|
| Acute ischemic lesions | 61.9% (50.7–71.9%) | Most frequent finding: T2-hyperintense lesions with corresponding restricted diffusion on DWI |
| Cerebral microbleeds | 52.9% (41.6–63.9%) | Rounded foci ≤10 mm on T2*-weighted GRE or SWI |
| Hemorrhagic lesions | 24.7% (15.1–37.9%) | Acute or chronic subarachnoid hemorrhage, intracerebral hemorrhage, or hemorrhagic transformation of ischemic stroke |
| Brain abscess or meningitis | 9.5% (5.6–15.6%) | — |
| Intracranial mycotic aneurysm (on MRA) | 6.2% (4.0–9.4%) | — |
Clinical significance
Cerebral MRI findings can change management, including upgrading the diagnostic classification of IE and modifying therapeutic or surgical plans: MRI led to modification of the therapeutic plan in 12.8% (95% CI 6.5–23.7%) and of the surgical plan in 14.2% (95% CI 8.2–23.4%) of cases, in six and five studies respectively.[4]
MRI protocols for suspected IE often include DWI, SWI, full-coverage time-of-flight imaging, contrast-enhanced MRA, and 3D contrast-enhanced T1-weighted imaging, along with axial T1-, T2-weighted and FLAIR sequences.
Antimicrobial considerations
The principal agents preferred by authors — covering methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), streptococci, and most enterococci — are vancomycin or daptomycin.
| Agent | Rationale |
|---|---|
| Vancomycin (IV) | The principal agent most authors use: the most evidence, and coverage of the key organisms including MRSA; covers coagulase-negative staphylococci in prosthetic valve cases. |
| Daptomycin (IV) | Similar spectrum to vancomycin with possible pharmacokinetic advantages; an acceptable alternative, especially for MRSA. |
| Linezolid (IV) | An alternative if vancomycin and daptomycin are precluded (e.g., allergy or resistance concerns) or where maintaining IV access is challenging. |
| Agent | Rationale |
|---|---|
| Ceftriaxone (IV) | Superior coverage of streptococci and HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella); covers Gram-negative and Gram-positive organisms. |
| Cefazolin (IV) | Used if MSSA is suspected or when combination coverage is needed; synergistic for MRSA with vancomycin or daptomycin. Many authors prefer cefazolin over anti-staphylococcal penicillins for MSSA because of lower toxicity. |
| Cefepime, piperacillin–tazobactam, carbapenems (IV) | Considered particularly for early prosthetic valve endocarditis (PVE, <3 months after surgery), driven by local nosocomial Gram-negative microbiology and potential pseudomonal coverage. Carbapenems offer the broadest coverage but should be reserved for resistant bacteria. |
| Agent | Setting | Dose |
|---|---|---|
| Vancomycin (IV) | Loading dose (normal kidney function) | 25–30 mg/kg IV (maximum 3 g) |
| Vancomycin (IV) | Maintenance (normal kidney function) | 15–20 mg/kg IV every 8–12 hours |
| Vancomycin (IV) | Target trough | 15–20 mg/L |
| Daptomycin (IV) | Suspected MRSA (S. aureus) | 8–10 mg/kg total daily dose |
| Daptomycin (IV) | Suspected Enterococcus spp. | 10–12 mg/kg total daily dose |
| Cefepime (IV) | Empirical coverage (AHA/ESC) | 2 g every 8 hours |
Empiric need to cover the CSF/brain?
High-level CNS coverage is highly relevant in IE because neurologic complications are the most common extracardiac complications, affecting up to 55% of patients: ischemic or hemorrhagic stroke, brain abscess, meningitis, and intracranial mycotic aneurysms.
However, the sources do not explicitly recommend starting therapy with special CNS penetration empirically, before CNS involvement is confirmed. Instead, imaging — specifically cerebral MRI — is used to detect these embolic events.
So while neurologic risk is extremely high, the empirical regimen focuses first on eradicating the primary (cardiac) source; specific adjustment for CNS penetration is usually a reaction to confirmed neurological involvement rather than a uniform empirical requirement — although agents like ceftriaxone have favourable characteristics.
- CNS involvement triggers therapeutic modification: when imaging detects CNS complications, treatment and surgical planning change — in one case, by adding a high-cerebral-diffusion antibiotic.
- Antibiotic selection: core empiric regimens target the endocarditis organisms, but drugs like ceftriaxone (often chosen as a secondary agent for streptococci and HACEK) typically have good CNS penetration, which may offer incidental coverage of neurological infection.
- Imaging and consultation: patients with neurologic symptoms should have cerebral MRI. If an embolic stroke or intracranial bleeding is found, consult neurology and/or neurosurgery — cardiac surgery may be delayed (up to 4 weeks for hemorrhagic stroke) because of the risk of expanding the stroke or hemorrhagic conversion during the operation.
References
- McDonald EG, et al. Guidelines for diagnosis and management of infective endocarditis in adults. JAMA Netw Open. 2023;6:e2326366.
- Hubers SA, DeSimone DC, Gersh BJ, Anavekar NS. Infective endocarditis: a contemporary review. Mayo Clin Proc. 2020;95:982–997.
- Brien L, Tierney C, Thompson-Brazill K. Current diagnosis and management of infective endocarditis in adults. J Nurse Pract. 2025;21:105494.
- Ahn Y, et al. Impact of brain MRI on the diagnosis of infective endocarditis and treatment decisions: systematic review and meta-analysis. AJR Am J Roentgenol. 2022;218:958–968.
- Singh SSA, et al. A narrative review of diagnosis of infective endocarditis — imaging methods and comparison. Ann Transl Med. 2020;8:1621.